Among a subset of Third International Stroke Trial participants, alteplase treatment was associated with higher mortality within the first week after stroke and lower mortality afterward.
Numerous randomized trials have assessed thrombolytic therapy for the treatment of acute ischemic stroke. Pooled analyses from these trials indicate that alteplase treatment improves functional outcomes, but the effect on survival remains unclear. Investigators now report the results of long-term follow-up among a subset of participants in the Third International Stroke Trial (IST-3).
Of the 3035 participants in IST-3, 1946 were enrolled in the United Kingdom, Sweden, or Norway, and their vital status after the end of trial participation could be ascertained through national mortality registries. Using these registries, investigators evaluated the association between alteplase treatment and mortality, first during the entirety of follow-up a…
Reviewing Author
DisclosuresSpeaker’s bureauGenentech
Grant / Research supportNational Institutes of Health/National Institute of Neurological Disorders and Stroke; Michael Goldberg Stroke Research Fund
Editorial boardsPLOS One; Scientific Reports
Leadership positions in professional societiesNeurocritical Care Society (Research Committee Member)
DisclosuresSpeaker’s bureauGenentech
Grant / Research supportNational Institutes of Health/National Institute of Neurological Disorders and Stroke; Michael Goldberg Stroke Research Fund
Editorial boardsPLOS One; Scientific Reports
Leadership positions in professional societiesNeurocritical Care Society (Research Committee Member)